AbbVie (NYSE:ABBV – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Earnings and Valuation
This table compares AbbVie and VistaGen Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbbVie | $61.16 billion | 7.53 | $4.23 billion | $3.54 | 73.64 |
| VistaGen Therapeutics | $1.27 million | 8.60 | -$69.68 million | ($1.66) | -0.15 |
Volatility and Risk
AbbVie has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
Insider and Institutional Ownership
70.2% of AbbVie shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for AbbVie and VistaGen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbbVie | 0 | 5 | 19 | 2 | 2.88 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
AbbVie presently has a consensus target price of $275.95, suggesting a potential upside of 5.86%. VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 285.87%. Given VistaGen Therapeutics’ higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than AbbVie.
Profitability
This table compares AbbVie and VistaGen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbbVie | 9.80% | -422.07% | 14.34% |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
Summary
AbbVie beats VistaGen Therapeutics on 9 of the 15 factors compared between the two stocks.
About AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
